Journal of Vascular Surgery
Volume 51, Issue 3 , Pages 736-746, March 2010

Adaptive changes in autogenous vein grafts for arterial reconstruction: Clinical implications

  • Christopher D. Owens, MD, MSc

      Affiliations

    • Corresponding Author InformationReprint requests: Christopher D. Owens, MD, MSc, University of California San Francisco, Division of Vascular and Endovascular Surgery, 400 Parnassus Avenue, San Francisco, CA 94143

Division of Vascular and Endovascular Surgery, University of California San Francisco, San Francisco, Calif

Received 5 July 2009; accepted 24 July 2009. published online 19 October 2009.

Richard P. Cambria, MD, Section Editor

Article Outline

For patients with the most severe manifestations of lower extremity arterial occlusive disease, bypass surgery using autogenous vein has been the most durable reconstruction. However, the incidence of bypass graft stenosis and graft failure remains substantial and wholesale improvements in patency are lacking. One potential explanation is that stenosis arises not only from over exuberant intimal hyperplasia, but also due to insufficient adaptation or remodeling of the vein to the arterial environment. Although in vivo human studies are difficult to conduct, recent advances in imaging technology have made possible a more comprehensive structural examination of vein bypass maturation. This review summarizes recent translational efforts to understand the structural and functional properties of human vein grafts and places it within the context of the rich existing literature of vein graft failure.

 

With the changing demographics of an aging population and a near-epidemic of diabetes mellitus, the prevalence of peripheral arterial disease (PAD) now approaches between 9 to 12 million Americans.1, 2 Among established treatments for advanced PAD, the autogenous vein bypass graft has been both the clinical standard and the most comprehensively studied revascularization strategy. Nevertheless, 30% to 50% of saphenous vein grafts fail during the intermediate period from 1 to 18 months postimplantation. This period is the most active from a biologic standpoint and the culprit lesion is intimal hyperplasia (IH). It is clear that IH is universal to all implanted vein grafts but why it becomes pernicious and progresses to clinical stenosis at some locations in some veins while others are relatively spared is not clear. In addition, all vein grafts undergo structural remodeling of the lumen and wall to some extent during this same time period. Long-term patency of the vein graft likely depends on adequate adaptation into the arterial environment as well as a relative moderation in the development of IH.

For well over 50 years, surgeon-scientists have studied histopathologic changes in the vein after implantation, developed animal models, documented efficacy of vein bypass, and with the aid of modern biology techniques, elucidated molecular signaling pathways involved in IH. With the later, came the potential of genetic engineering of the vein graft and the promise of improving patency through novel therapeutics with specific molecular strategies.3, 4, 5 For example, the PRoject of Ex-Vivo graft ENgineering via Transfection III (PREVENT III) was a phase III study employing an antisense DNA decoy molecule to the transcription factor E2F. This randomized, placebo-controlled, double blinded trial was specifically powered to detect a significant difference in vein graft patency in a cohort of over 1400 patients with critical limb ischemia (CLI). In this contemporary study, the overall 1-year primary patency rate was 61% – a value that has not changed for the past several decades.6 While this trial ultimately failed to meet its primary efficacy endpoint, it underscored our lack of understanding of the pathophysiology of vein graft failure perhaps by underestimating the complexity and redundancy in the molecular elements contributing to IH or neglecting other potential variables such as remodeling.4, 6

Advances in imaging technology during the last decade such as high resolution ultrasound scans, 3-dimensional magnetic resonance imaging (3D-MRI), and intravascular ultrasound scans have greatly facilitated our ability to study human vein bypass grafts in vivo.7, 8 These modalities have the ability to reliably resolve submillimeter structures.8, 9, 10 Serial changes in the vein graft structure and function can be quantified and patterns of normal and abnormal adaptation can be discerned. Beyond luminal changes, wall thickness can now be determined and mathematic models constructed building on the rich existing experimental data compiled from animal and histomorphologic studies from the last 4 decades.

Herein, recent advances to better understand the pathogenesis and subsequent evolution of vein graft failure are outlined. Importantly, in vivo observations are emphasized and placed within a historic and a clinical context whenever possible.

Back to Article Outline

The human saphenous vein and the universal response to injury 

The normal in vivo appearance of the human saphenous vein is a light blue, thin-walled structure that easily distends with minimal pressure. Unfortunately, many veins used in bypass grafting have pre-existing lesions such as endothelial damage, medial hypertrophy, or intimal thickening which may give them a slightly sclerotic appearance.11, 12 This creates considerable variability in the normal (usable) range of vein wall thickness from 180 to 650 μm.13 While severe changes render the vein unusable, the impact of subtle pre-bypass morphologic changes on the future development of vein graft stenosis is not known, though decreased compliance has been shown to be associated with early vein graft failure.14 The focal nature of vein graft stenosis detected by surveillance ultrasound scan studies suggests that predisposing lesions may exist in these areas.15

Intimal hyperplasia was first described in veins by the Nobel prize winning physician Alex Carrel in 1906 and is generally regarded as the universal injury response to a blood vessel: regardless of the injury or the vessel.16 It is thought to be due to a proliferation of smooth muscle cells (SMCs) which have undergone a phenotypic switch from a quiescent, contractile phenotype to that of a synthetic migratory phenotype. The source of the SMCs which contribute to the intimal hyperplasia has long been thought to be from the media of the vessel wall but the identification of graft-extrinsic cells such as periadventitial fibroblast or circulating precursor cells has challenged this concept.17, 18, 19, 20, 21, 22 Production of extracellular fibrous matrix and ground substance by synthetic SMCs leads to a progressive increase in intimal and medial fibrosis, reduction in cellularity, and overall stiffening of the vein graft which may subsequently limit the graft's ability to properly remodel in the arterial circulation. The endothelial cells play a key role in the regulation of intimal growth by a number of tonic growth-inhibitory mechanisms.23, 24 Endothelial cell loss or damage markedly attenuates these growth modulating effects.

Biologic mediators are also involved.25 Liberated growth factors from platelets lining the injured vessel wall, infiltration of inflammatory cells through the permeable endothelial cell layer, circulating inflammatory molecules, and endothelial dysfunction are likely operative.26, 27, 28 The platelet-endothelium interaction is emphasized by the effectiveness of platelet inhibitors in preventing the early and late occlusion of vein grafts.29, 30

The harvesting and preparation of the saphenous vein for bypass surgery affords ample opportunity to impart injury. Mechanical manipulation, valve lysis, pressure distension, ischemia/reperfusion, devascularization and denervation, and transposition into the arterial environment contribute to the injury of the vein.31, 32, 33 A number of intraoperative techniques have been employed in an attempt to mitigate the venous injury. These include no-touch harvesting technique, venous storage solutions such as the University of Wisconsin solution, as well as placing veins in the in situ configuration to theoretically decrease manipulation and warm-ischemia time.34, 35, 36, 37, 38 In general, it is felt that storage in a papaverine-treated, tissue culture solution, gentle harvesting, and the use of controlled distension decreases endothelial injury and possibly subsequent IH formation.39

The causal relationship between arterial hemodynamics and IH is well established and, in a sense, fulfills Koch's postulates. For example, Brody et al40 demonstrated that veins transposed into the arterial circulation developed IH, whereas those dissected and re-anastomosed to the venous circulation did not. Experimental vein grafts explanted from the arterial circulation and subsequently transferred back to the venous circulation demonstrated regression of IH.41, 42, 43, 44 Finally, vein grafts placed in a low-flow, high-resistance environment developed an exuberant IH response that regressed once placed into a normal flow environment.45 These experiments suggest that the cyclic mechanical forces of the arterial circulation are sufficient and necessary for the development of IH rather than simply the injury of dissection.

Evidence from animal models consistently show that the IH thickness of a vein graft varies inversely proportional to the magnitude of shear stress across the endothelial cell surface.45, 46, 47, 48, 49, 50, 51, 52, 53 In one study, vein grafts exposed to 50% less shear stress had a 63% thicker intimal layer after 4 weeks.48 Vein grafts placed in conditions of high shear stress demonstrated more endothelium-dependent relaxation suggesting that higher shear stress favorably improved endothelial function, possibly through increased nitric oxide (NO) production.47, 54, 55

The kinetics of IH development have also been studied in the rabbit and canine vein graft models.22, 56 There is an initial burst of endothelial and smooth muscle cell proliferation occurring within 1 week following implantation and a return to the baseline quiescent state by week 12. More recently, mathematical relationships of the temporal sequence of the development of IH as a function of shear stress and time, h(t, τ) = ho+(RL[1-e−A(t-t*)])/(1+BτC), where h is the intimal thickness, t is time, τ is shear stress, ho is the intimal thickness at the time of implantation, RL is the initial lumen radius, and t* is the time when intimal thickness begins to change. A, B, and C are experimentally derived constants and, therefore, unique to the model used.57, 58 The application of mathematical models of this type, validated in human vein grafts, would be of great benefit in the determination of efficacy of new therapeutics or biologics developed to inhibit IH.

Back to Article Outline

The importance of vein graft caliber regulation 

While much attention has been given to IH as the primary mode of failure for vein grafts, relatively limited information is available on the role remodeling plays in the failing vein graft.6, 7, 10, 59, 60 Remodeling is defined as a dynamic structural and biochemical adaptation within the vein graft that results in long-term changes in lumen caliber, wall thickness, composition of matrix proteins, and endothelial cell reactivity.7, 61, 62, 63, 64, 65, 66, 67 Remodeling is dependent on an interaction between locally and remotely generated growth factors, vasoactive substances, and hemodynamic stimuli.22, 68

It is well known that arteries undergo compensatory remodeling in response to hemodynamic forces.69, 70, 71, 72, 73, 74, 75 The resulting change in lumen caliber or wall thickness is thought to maintain these forces at a biologically preset value that promotes maximum efficiency of blood transport.69, 70 Between the predominant hemodynamic forces, wall tension and shear stress, the later appears to be the dominant of the two in regulating lumen caliber.76 While blood flow is proportional to the product of the vessel's radius and the pressure gradient across the vessel, shear stress is proportional to the quotient of blood flow and lumen radius. Shear stress is the frictional force per unit area tangential to the vessel wall and, therefore, “sensed” by endothelial cells. Endothelial cells are the recognized biosensor of the vessel and align themselves along the direction of shear stress. Steady laminar shear stress has a healthy trophic effect on the endothelial cells by inhibiting leukocyte adhesion, promoting vasodilator production such as NO77 and prostacyclin,78 limiting SMC hyperplasia,79 and decreasing platelet aggregation.80 Conversely, low shear stress and turbulence associated with complex geometries such as anastomosis and valves, has the opposite effect.81 Removal of the endothelium abolishes flow-dependent vasodilation.82

A vein implanted into the arterial circulation will experience a several-fold increase in both shear stress and wall tension. Several lines of evidence argue that hemodynamic regulation of venous structures exist.74, 83, 84, 85 In a rabbit jugular vein – carotid artery interposition model, the lumen radius increased 57% over a 24-week study period: a magnitude sufficient to reduce the initially high shear stress down to that of a normal rabbit carotid artery.56 The remarkable rapidity in which the vein remodels after implantation in the arterial circulation was exemplified in a canine model whereby maximal diameter was attained in just 7 days.22

The ability for human saphenous vein grafts to dilate substantially – and sometimes pathologically – after implantation has been known from autopsy studies for nearly 50 years.86 Fillinger et al87 demonstrated that final lumen diameter attained at 12 months was a function of the initial lumen diameter and shear stress. While vein grafts, which had the highest initial shear stress, tended to be smaller at the time of implantation, they underwent greater lumen dilation then those with lower initial shear stress. This observation is important to consider when choosing to use or discard a relatively small vein, as it is well known that the luminal size of the vein is of primary importance for subsequent patency.88, 89 However, a small vein, free of pre-existing pathology, that is compliant and distends easily will likely dilate and function well as a bypass graft.

More recently, quantification of human vein graft lumen remodeling has been assessed using a high-resolution ultrasound scan. It has been shown that the vein graft lumen, on average, dilates about 22% over the first 6 months of implantation (Fig 1, A).10 The most pronounced period of luminal change was during the first 30 days. However, considerable variability existed in luminal dilation (range, −31% to +64%) as evidenced by the fact that a substantial minority (28%) of the vein grafts actually decreased in size during this time frame (Fig 1, B). Importantly, loss of vein graft lumen size – negative remodeling – during the first month was associated with earlier loss of primary patency compared to those veins which underwent luminal dilation. Therefore, it appears that the ability of vein grafts to adequately dilate in the early period of implantation is critical to ensure long-term patency. Not surprisingly, shear stress correlated with early vein graft lumen remodeling (Fig 1, C).10 Those with higher initial shear stress dilated to a greater extent than those with less.

  • View full-size image.
  • Fig 1. 

    A, While the mean bypass graft lumen increases about 22% over the first 6 months following implantation. B, Considerable variability exists between individual grafts. C, Early luminal remodeling is correlated with initial shear stress at the time of implantation. D, Temporally distinct from luminal remodeling, the vein graft significantly stiffens between 1 and 3 months following implantation. Adapted from Reference 10.

Taken together, these data indicate that laminar shear stress acting through endothelium-dependent mechanisms not only attenuates the development of over-exuberant IH, but also influences vein graft lumen caliber regulation; perhaps through common mediators such as NO, prostanoids, or hyperpolarizing factors.22, 50, 54, 55, 90

Back to Article Outline

The influence of inflammation 

It has long been recognized that the implantation of a vein in the arterial circulation is accompanied by a local inflammatory response within the vein graft wall.27, 91 But the effects of systemic inflammation on the incidence of vein graft stenosis is unknown and has only recently been investigated in a cohort of patients undergoing lower extremity revascularization exclusively with autogenous constructs.92, 93 In this study, three biomarkers of inflammation, high sensitivity C reactive protein (hs-CRP), serum amyloid A (SAA), and fibrinogen were examined. While all three were associated with the severity of PAD at the time of presentation, with diabetes and renal failure, only hs-CRP was found to be independently associated with adverse events following bypass surgery, most of which were vein-graft related.92

Among all inflammatory markers, the hs-CRP test is the most validated, most widely available, and the only test endorsed by the American Heart Association (AHA) and Center for Disease Control as a cardiovascular risk marker.94 The AHA has determined that the hs-CRP test is appropriate for patients with intermediate risk of cardiovascular events and that values of 0-1 mg/L, 1-3 mg/L, and >3 mg/L would place patients in low, medium, and high-risk categories, respectively. However, PAD is considered to be a coronary heart disease equivalent and these patients are already considered high risk. Indeed, patients undergoing lower extremity bypass surgery have a median hs-CRP (3.25 mg/L) and, therefore, the AHA guidelines would not be appropriate for this population.92 Rather, a cutoff value of hs-CRP at 5 mg/L has more potent discriminating ability with respect to adverse outcomes than hs-CRP placed in tertiles, according to the AHA recommendations, or another cutoff value.

It is still unclear whether CRP is simply a marker of inflammation or a biomodulator of vein graft biology. However, vein grafts in patients with high CRP do not dilate as much as would be expected to shear stress.93 Dichotomizing patients undergoing bypass surgery with autogenous vein by preoperative plasma CRP concentration, individuals with high CRP levels (>5 mg/L) had significantly less vein graft luminal dilation in the first month after surgery compared to patients with CRP below 5 mg/L, 10% vs 37% (Fig 2).93 Further, the significant positive correlation between shear stress and vein graft luminal remodeling was no longer present in the individuals with higher levels of CRP. Hence, patients with high levels of systemic inflammation have impaired ability to positively remodel vein grafts, possibly by impairing endothelial function. These studies are ongoing and the contention that inflammation, per se, can be used as a surrogate biomarker for graft-specific failure remains to be proven.

  • View full-size image.
  • Fig 2. 

    Vein graft lumen change (percent) from implantation to 1 month in a population undergoing lower extremity bypass grafting for arterial occlusive disease. Luminal measurements were made with high resolution M-mode ultrasound at the same location of the vein graft for the operative and the 1 month assessment. By dichotomizing the population by baseline plasma CRP levels above and below 5 mg/L, disparate early luminal remodeling patterns of the vein graft become apparent, 37% vs 10%, P = .0072. Thus, patients with high levels of systemic inflammation have impaired ability to positively remodel vein grafts, adapted from Reference 93.

However, many lines of evidence suggest that systemic inflammation impairs endothelial function in patients with PAD with significant clinical consequences. A C-reactive protein has been shown to be associated with impaired brachial artery flow mediated, endothelium dependent, vasodilation (FMD) in patients with PAD.95, 96, 97 Further, in a cohort of patients undergoing vascular surgery, impaired FMD has been shown to be independently associated with adverse 30-day cardiovascular outcomes.98, 99 Whether or not intensive perioperative reduction of inflammation such as with high-dose statin therapy would improve clinical outcomes in this population, remains to be studied.

Back to Article Outline

Endothelial function 

Animal studies have demonstrated that veins are capable of relaxation and contraction to vasoactive mediators but to a lesser extent than similarly sized arteries.100, 101, 102, 103, 104 The thinner media or the histologic arrangement of SMCs and fibrous protein may be responsible. Vascular responses of the human great saphenous vein (GSV) to vasoactive mediators has been studied using acetylcholine (Ach) or the calcium ionophore A23187 to elicit endothelium-dependent vasodilation.105, 106, 107 In general, the GSV can generate as much contractile force in response to phenylephrine as the internal mammary artery – about 8 to 10 grams. However, precontracted GSVs exhibit variable relaxation with Ach and a more pronounced relaxation to A23187.105, 106

However, the underlying hypothesis that vein graft endothelial function is a critical regulator of final luminal caliber, and ultimately patency, remains to be proven. Veins excised during redo coronary bypass grafting108 or during revision of lower extremity vein graft stenosis109 have demonstrated altered smooth muscle cell contractility and the absence of relaxation to Ach.105, 108, 109 However, these specimens were diseased and the clinical relevance is uncertain. Ku et al110 studied functioning vein grafts with patent lumens that were 7 months to 12 years in age excised from patients undergoing heart transplantation. Several important observations are noteworthy from this study. First, all vein grafts exhibited vasorelaxation to Ach though with considerable variability, −9% to −65% of the precontracted state existed between different grafts. Second, there was significant variability even within a single vein-graft segment indicating local heterogeneity in NO production along the course of the vein graft. And third, vein grafts with the most pronounced IH exhibited the least amount of endothelium-dependent relaxation. These observations suggest that a functional endothelial lining is regenerated in human vein grafts, that it is not constant along the length of the vein graft, and that IH is at least associated with endothelial impairment.111

These findings may be one explanation of the focal nature of most vein graft lesions. While diffuse IH occlusive disease may occur in approximately 12% of vein grafts, the majority of culprit lesions are focal and often perianastomotic (Fig 3).15, 16, 35 A focal deficiency in NO from either pre-existing lesions, primary endothelial injury, or turbulent flow with altered shear stress, may result in an area of the graft that fails to sufficiently remodel.31, 33, 112, 113, 114 The cumulative result of the relative deficiency of NO would be increased IH,79, 115 decreased remodeling,116 and possibly an increase in collagen production,117, 118 thereby stiffening the vein graft and further reducing the ability to dilate. Hence, the wall would thicken disproportionately to the lumen dilatation producing the clinically familiar focal stenosis within a segment of the vein graft (Fig 4).

  • View full-size image.
  • Fig 3. 

    Modes of vein graft failure. While the majority of intimal hyperplasia in vein grafts is focal, a substantial minority (12%) is diffuse. A, Represents a 6-month-old vein graft in a 67-year-old white man that developed a midgraft stenosis (arrow) that was successfully treated with a vein patch angioplasty. B, Represents a 4-month-old vein graft in a 77-year-old black women undergoing angiography for contralateral limb ischemia. C, Three months later, she developed diffuse intimal hyperplasia which progressed to vein graft occlusion.

  • View full-size image.
  • Fig 4. 

    Histologic sections (×10) of an 8-month-old vein graft which developed a focal midgraft stenosis and underwent open revision with a short interposition graft. The vein was of uniform size and caliber at the time of implantation. A, The sections were taken approximately 2 cm from one another. The area of stenosis has developed marked intimal hyperplasia and has a smaller area circumscribed by the internal elastic laminae as well as decreased total vessel diameter indicative of negative remodeling of the entire vein graft. B, Theoretical normal and abnormal adaptation patterns of a human lower extremity vein grafts. Normally the lumen and wall area increase in the early postimplantation period to produce a lumen diameter to wall thickness ratio of about 7.

Detection of the more physiologically-relevant flow-stimulated endothelial function has recently been tested in vivo in a cohort of patients with mature (>1 year since implantation) femoropopliteal vein grafts that have not undergone revision. The technique was similar to the one employed to test brachial artery FMD which is known to be endothelium-dependent and mediated by NO.119 Assessment of endothelial function by brachial artery flow-mediated dilation is a well-established research tool which measures small changes in brachial artery diameter in response to an increase in blood flow. By applying an occlusive blood pressure cuff over the proximal calf for 5 minutes, a hyperemic response (increase in blood flow and shear stress) was stimulated in the leg upon its release (Fig 5). High resolution ultrasound scan and postprocessing imaging software was then used to carefully measure vein graft blood flow, shear stress, and lumen diameter before and after the hyperemic response and, therefore, calculate FMD in the vein graft. Hyperemia resulted in a 233% increase in volumetric flow through the vein graft above baseline in this experiment.120 This study showed, we believe for the first time, that vein grafts did dilate to an increase in blood flow. Vein graft FMD was 5.28% ± 3.1% (range, 1.99-4 9.36%), for the entire cohort (Fig 5). The specificity of NO as the mediator of this response was established by intravenously administering the NO-inhibitor NG L-monomethyl arginine (L-NMMA), during a subsequent test which abolished the FMD response in all vein grafts.

  • View full-size image.
  • Fig 5. 

    Flow mediated vasodilation in mature human saphenous vein grafts demonstrates a functional endothelium. A, Application of an occlusive blood pressure cuff (220 mm Hg) to the proximal calf of a cohort of patients undergoing femoro-popliteal bypass grafts for 5 minutes produces an increase in blood flow and shear stress within the graft. B, In this cohort, flow mediated, endothelium dependent vasodilation was 5.3% and nitroglycerin mediated, endothelium independent (0.4 mg sublingual nitroglycerin) dilation was 3.7%.

These studies demonstrate that vein grafts have a biologically active endothelial layer which can be assessed by noninvasive techniques. The relationship of endothelial cell function, the extent, and timing of its recovery of function, and patency of the vein graft remains to be seen and is an area of ongoing investigation. It is provocative to speculate that pharmacologic adjuncts, provided locally or remotely, to improve endothelial function and NO availability may decrease IH, improve remodeling, and increase vein graft patency.

Back to Article Outline

The vein graft wall 

While shear stress is the dominant regulator of lumen caliber, wall tension is the more critical determinant of wall thickness. Animal models indicate that there is a structurally optimal lumen radius/wall thickness ratio to support arterial pressure with minimal wall stress. Indeed, there is a remarkable consistency of tension per lamellar unit of the aortic media across diverse mammalian species from the mouse to man.121 In a rabbit vein graft model, the ratio of lumen radius to wall thickness (ri/h), initially very high at the time of implantation, approached that of the normal carotid artery by 24 weeks.56 In humans, vein graft lumen diameter to wall thickness ratio, about 9:1 at the time of implantation, is reduced to 7.4 at 6 months, a value close to that of the superficial femoral artery (Table).122 Until recently, accurate in vivo measurement of the vein graft wall has been elusive. However, high-resolution 3-D MRI with superior signal-to-noise ratio, is capable of resolving structures as small as 300 microns within the range of the vein graft wall.8 By simultaneously measuring wall thickness and lumen radius at 1 and 6 months postimplantation, a very strong correlation existed between luminal enlargement and total vessel enlargement.120 The equation ΔLD = 0.62(ΔOD) to 0.02, where LD is lumen diameter and OD is total vein graft outer diameter, relates changes in luminal diameter to changes in total vessel diameter. This linear regression equation relates what should happen to the lumen of a normal patent bypass graft given a measurable change in the vein graft wall. For example, a 22% increase in the lumen diameter should be accompanied by a 35% increase in the outer diameter of the vein graft. A slope substantially less than 0.62 would indicate excessive thickening of the wall or insufficient lumen dilation.

Table. Remodeling of human saphenous vein graft, 0-6 month
Implantation6 monthsSFA
LD (mm)3.74.56.8
Stiffness (Mdynes/cm)2.03.31.7
Wall thickness (μm)410610870
LD/WT9.07.47.8

LD, Lumen diameter; WT, wall thickness.

Systematic studies of human vein grafts with aid of modern high-resolution imaging technology provide insight into vein adaptation in the arterial environment. It has become clear that vein remodeling constitutes changes in luminal and total vessel diameter. The forces and flows responsible for these changes are becoming clear but other factors are involved as well. As can be seen in Fig 4, segments of a vein graft with near occlusive IH also had a smaller total vessel diameter compared with a normal adjacent segment. Therefore, in this particular case, the stenosis was due to a combination of negative remodeling and IH. Further studies are needed in this important area.

Back to Article Outline

Clinical science 

Translational advances notwithstanding, there has been much improvement in the clinical sciences of vein graft outcomes. Hypothesis-driven, multi-centered trials,6 national databases with quality measures,123 and comparative effectiveness trials124 have replaced single-center retrospective studies and promise to be more reflective of real world practice. These trials, when carefully conducted, can potentially bridge the bench to bedside translational gulf and careful observations of the results can often be hypothesis generating. For example, PREVENT III alone has resulted in 10 published manuscripts of outcomes in patients with CLI examining quality measures, resource utilization, racial disparities, technical considerations, and risk estimation scores.6, 89, 125, 126, 127, 128, 129, 130, 131, 132

Long-term results from the Bypass vs Angioplasty in Severe Ischemia of the Leg (BASIL) trial emphasize that the more durable reconstruction with a vein graft translates into improved outcomes compared to less invasive alternatives.124, 133 However, technical factors such as smaller diameter and longer bypass grafts experience more graft-related events (GRE), and GREs result in decreased quality of life (QoL) and increased resource utilization emphasizing the importance of patency as an outcome measure.89, 128 A priori identification of vulnerable grafts through the use of biochemical and imaging biomarkers may provide an opportunity for targeted therapy or, at the very least, identify patients who would benefit from a more intensive surveillance program. Surrogate endpoints such as novel methods of detection of vein endothelial health (function), IH kinetics, and normal and abnormal remodeling patterns will improve our understanding of the mechanisms of action for the next biologic or new clinical entity to emerge to improve vein graft patency.

Results from clinical trials may have significant biologic implications. For example, gender and racial disparity, often overlooked in single-centered studies due to small sample size, can be examined in multicentered cohorts. While it is well known that PAD disproportionately affects black patients, less is known about graft specific outcomes. In the PREVENT III database, patients with black race and female gender were at increased risk of graft occlusion and had inferior limb salvage, but there were no differences in primary patency compared with white patients.125 This finding suggests that the disease process is more aggressive, possibly more diffuse, and, therefore, lower rates of graft salvage by revisions once IH stenosis developed or surgeons were quicker to abandon the graft. An altered biologic healing response to the implanted graft, possibly through increased inflammation, altered thrombogenicity, or differential endothelial cell responses may be responsible.134, 135, 136, 137, 138 Thus observations from clinical trials such as these can directly stimulate basic scientific efforts.

Back to Article Outline

Conclusion 

Beyond the risk of limb loss, decreased graft patency results in increased resource utilization128 and significantly impacts QoL.127 Our current pharmacopoeia has not made any significant impact on the natural history of vein graft stenosis emphasizing the need for a better mechanistic understanding of graft failure.139 Animal models and mathematical constructs should incorporate structural as well as functional changes of the maturing vein graft. Understanding the relative contributions of IH and remodeling are not simply academic, as molecular therapeutics targeted at IH will likely not improve remodeling. Multidisciplinary translational research programs leveraging recent advances in biomedical imaging, molecular technology, and genetic engineering will likely dramatically increase our understanding of this vexing problem.

Back to Article Outline

Author contributions 


Conception and design: CO

Analysis and interpretation: CO

Data collection: CO

Writing the article: CO

Critical revision of the article: CO

Final approval of the article: CO

Statistical analysis: CO

Obtained funding: CO

Overall responsibility: CO

Back to Article Outline

 

I would like to thank Michael Belkin, MD, and Michael S. Conte, MD, for continued support and mentorship.

Back to Article Outline

References 

  1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  3. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation. 2001;103:1618–1623
  4. Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg. 2002;36:1040–1052
  5. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98:82–89
  6. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751discussion 751
  7. Kaneda H, Terashima M, Takahashi T, Iversen S, Felderhoff T, Grube E, et al. Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study. Am Heart J. 2006;151:726–729
  8. Mitsouras D, Mulkern RV, Owens CD, Conte MS, Ersoy H, Luu TM, et al. High-resolution peripheral vein bypass graft wall studies using high sampling efficiency inner volume 3D FSE. Magn Reson Med. 2008;59:650–654
  9. Rybicki FJ, Mitsouras D, Owens CD, Whitmore AG, Ersoy H, Mulkern RV, et al. Lower extremity peripheral vein bypass graft wall thickness changes demonstrated at 1 and 6 months after surgery with ultra-high spatial resolution black blood inner volume three-dimensional fast spin echo magnetic resonance imaging. Int J Cardiovasc Imaging. 2008;24:529–533
  10. Owens CD, Wake N, Jacot JG, Gerhard-Herman M, Gaccione P, Belkin M, et al. Early biomechanical changes in lower extremity vein grafts--distinct temporal phases of remodeling and wall stiffness. J Vasc Surg. 2006;44:740–746
  11. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45–68
  12. Milroy CM, Scott DJ, Beard JD, Horrocks M, Bradfield JW. Histological appearances of the long saphenous vein. J Pathol. 1989;159:311–316
  13. Canham PB, Finlay HM, Boughner DR. Contrasting structure of the saphenous vein and internal mammary artery used as coronary bypass vessels. Cardiovasc Res. 1997;34:557–567
  14. Davies AH, Magee TR, Baird RN, Sheffield E, Horrocks M. Vein compliance: a preoperative indicator of vein morphology and of veins at risk of vascular graft stenosis. Br J Surg. 1992;79:1019–1021
  15. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. J Vasc Surg. 1993;17:195–204discussion 204-6
  16. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg. 1995;9:7–18
  17. Shi Y, O'Brien JE, Mannion JD, Morrison RC, Chung W, Fard A, et al. Remodeling of autologous saphenous vein grafts (The role of perivascular myofibroblasts). Circulation. 1997;95:2684–2693
  18. Shi Y, O'Brien JE, Ala-Kokko L, Chung W, Mannion JD, Zalewski A. Origin of extracellular matrix synthesis during coronary repair. Circulation. 1997;95:997–1006
  19. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89:1111–1121
  20. Zalewski A, Shi Y, Johnson AG. Diverse origin of intimal cells: smooth muscle cells, myofibroblasts, fibroblasts, and beyond?. Circ Res. 2002;91:652–655
  21. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol. 2004;24:470–476
  22. Kalra M, Miller VM. Early remodeling of saphenous vein grafts: proliferation, migration, and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J Vasc Res. 2000;37:576–584
  23. Ahanchi SS, Tsihlis ND, Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J Vasc Surg. 2007;45(Suppl A):A64–A73
  24. Davies MG, Klyachkin ML, Dalen H, Massey MF, Svendsen E, Hagen PO. The integrity of experimental vein graft endothelium–implications on the etiology of early graft failure. Eur J Vasc Surg. 1993;7:156–165
  25. Bratt J, Palmblad J. Cytokine-induced neutrophil-mediated injury of human endothelial cells. J Immunol. 1997;159:912–918
  26. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068–2101
  27. Eslami MH, Gangadharan SP, Belkin M, Donaldson MC, Whittemore AD, Conte MS. Monocyte adhesion to human vein grafts: a marker for occult intraoperative injury?. J Vasc Surg. 2001;34:923–929
  28. Gangadharan SP, Eslami MH, Weiss IP, Sui X, Conte MS. Monocyte adhesion to balloon-injured arteries: the influence of endothelial cell seeding. J Vasc Surg. 2001;33:1247–1254
  29. Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982;307:73–78
  30. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984;310:209–214
  31. Tsui JC, Souza DS, Filbey D, Karlsson MG, Dashwood MR. Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel “no-touch” technique: potential role of nitric oxide contribution to improved early graft patency rates. J Vasc Surg. 2002;35:356–362
  32. Quist WC, LoGerfo FW. Prevention of smooth muscle cell phenotypic modulation in vein grafts: a histomorphometric study. J Vasc Surg. 1992;16:225–231
  33. Hinokiyama K, Valen G, Tokuno S, Vedin JB, Vaage J. Vein graft harvesting induces inflammation and impairs vessel reactivity. Ann Thorac Surg. 2006;82:1458–1464
  34. Odashiro T, Komori K, Ishii T, Okadome K, Sugimachi K. Comparison of endothelial function between in situ and reversed vein graft: differences in endothelium-dependent responses. Surgery. 1995;117:179–188
  35. Bandyk DF, Schmitt DD, Seabrook GR, Adams MB, Towne JB. Monitoring functional patency of in situ saphenous vein bypasses: the impact of a surveillance protocol and elective revision. J Vasc Surg. 1989;9:286–296
  36. Leather RP, Shah DM, Chang BB, Kaufman JL. Resurrection of the in situ saphenous vein bypass (1000 cases later). Ann Surg. 1988;208:435–442
  37. Fogle MA, Whittemore AD, Couch NP, Mannick JA. A comparison of in situ and reversed saphenous vein grafts for infrainguinal reconstruction. J Vasc Surg. 1987;5:46–52
  38. Haudenschild C, Gould KE, Quist WC, LoGerfo FW. Protection of endothelium in vessel segments excised for grafting. Circulation. 1981;64(2 Pt 2):II101–II107
  39. Davies MG, Hagen PO. Influence of perioperative storage solutions on long-term vein graft function and morphology. Ann Vasc Surg. 1994;8:150–157
  40. Brody WR, Angeli WW, Kosek JC. Histologic fate of the venous coronary artery bypass in dogs. Am J Pathol. 1972;66:111–130
  41. Davies MG, Klyachkin ML, Dalen H, Svendsen E, Hagen PO. Regression of intimal hyperplasia with restoration of endothelium-dependent relaxing factor-mediated relaxation in experimental vein grafts. Surgery. 1993;114:258–270discussion 270-1
  42. Fann JI, Sokoloff MH, Sarris GE, Yun KL, Kosek JC, Miller DC. The reversibility of canine vein-graft arterialization. Circulation. 1990;82(5 Suppl):IV9–IV18
  43. Sterpetti AV, Cucina A, Lepidi S, Randone B, Stipa F, Aromatario C, et al. Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblastic growth factor production. J Vasc Surg. 1996;23:568–575
  44. Davies MG, Fulton GJ, Svendsen E, Hagen PO. Time course of the regression of intimal hyperplasia in experimental vein grafts. Cardiovasc Pathol. 1999;8:161–168
  45. Morinaga K, Eguchi H, Miyazaki T, Okadome K, Sugimachi K. Development and regression of intimal thickening of arterially transplanted autologous vein grafts in dogs. J Vasc Surg. 1987;5:719–730
  46. Morinaga K, Okadome K, Kuroki M, Miyazaki T, Muto Y, Inokuchi K. Effect of wall shear stress on intimal thickening of arterially transplanted autogenous veins in dogs. J Vasc Surg. 1985;2:430–433
  47. Cambria RA, Lowell RC, Gloviczki P, Miller VM. Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs. J Vasc Surg. 1994;20:765–773
  48. Galt SW, Zwolak RM, Wagner RJ, Gilbertson JJ. Differential response of arteries and vein grafts to blood flow reduction. J Vasc Surg. 1993;17:563–570
  49. Kohler TR, Kirkman TR, Kraiss LW, Zierler BK, Clowes AW. Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. Circ Res. 1991;69:1557–1565
  50. Kraiss LW, Kirkman TR, Kohler TR, Zierler B, Clowes AW. Shear stress regulates smooth muscle proliferation and neointimal thickening in porous polytetrafluoroethylene grafts. Arterioscler Thromb. 1991;11:1844–1852
  51. Meyerson SL, Skelly CL, Curi MA, Shakur UM, Vosicky JE, Glagov S, et al. The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft. J Vasc Surg. 2001;34:90–97
  52. Geary RL, Kohler TR, Vergel S, Kirkman TR, Clowes AW. Time course of flow-induced smooth muscle cell proliferation and intimal thickening in endothelialized baboon vascular grafts. Circ Res. 1994;74:14–23
  53. Dobrin PB, Littooy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery. 1989;105:393–400
  54. Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res. 1998;83:334–341
  55. Fisslthaler B, Dimmeler S, Hermann C, Busse R, Fleming I. Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress. Acta Physiol Scand. 2000;168:81–88
  56. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5:126–136
  57. Tran-Son-Tay R, Hwang M, Garbey M, Jiang Z, Ozaki CK, Berceli SA. An experiment-based model of vein graft remodeling induced by shear stress. Ann Biomed Eng. 2008;36:1083–1091
  58. Tran-Son-Tay R, Hwang M, Berceli SA, Ozaki CK, Garbey M. A model of vein graft intimal hyperplasia. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5807–5810
  59. Wong AP, Nili N, Jackson ZS, Qiang B, Leong-Poi H, Jaffe R, et al. Expansive remodeling in venous bypass grafts: novel implications for vein graft disease. Atherosclerosis. 2008;196:580–589
  60. Ge J, Liu F, Bhate R, Haude M, Görge G, Baumgart D, et al. Does remodeling occur in the diseased human saphenous vein bypass grafts? (An intravascular ultrasound study). Int J Card Imaging. 1999;15:295–300
  61. Nishioka T, Luo H, Berglund H, Eigler NL, Kim CJ, Tabak SW, et al. Absence of focal compensatory enlargement or constriction in diseased human coronary saphenous vein bypass grafts (An intravascular ultrasound study). Circulation. 1996;93:683–690
  62. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431–1438
  63. O'Brien JE, Ormont ML, Shi Y, Wang D, Zalewski A, Mannion JD. Early injury to the media after saphenous vein grafting. Ann Thorac Surg. 1998;65:1273–1278
  64. Hong MK, Mintz GS, Hong MK, Abizaid AS, Pichard AD, Satler LF, et al. Intravascular ultrasound assessment of the presence of vascular remodeling in diseased human saphenous vein bypass grafts. Am J Cardiol. 1999;84:992–998
  65. Caños DA, Mintz GS, Berzingi CO, Apple S, Kotani J, Pichard AD, et al. Clinical, angiographic, and intravascular ultrasound characteristics of early saphenous vein graft failure. J Am Coll Cardiol. 2004;44:53–56
  66. Mendelsohn FO, Foster GP, Palacios IF, Weyman AE, Weissman NJ. In vivo assessment by intravascular ultrasound of enlargement in saphenous vein bypass grafts. Am J Cardiol. 1995;76:1066–1069
  67. Leotta DF, Primozich JF, Beach KW, Bergelin RO, Zierler RE, Strandness DE. Remodeling in peripheral vein graft revisions: serial study with three-dimensional ultrasound imaging. J Vasc Surg. 2003;37:798–807
  68. Owens CD, Ho KJ, Conte MS. Lower extremity vein graft failure: a translational approach. Vasc Med. 2008;13:63–74
  69. Rodbard S. Vascular caliber. Cardiology. 1975;60:4–49
  70. Murray CD. The physiological principle of minimum work: I. The vascular system and the cost of blood volume. Proc Natl Acad Sci U S A. 1926;12:207–214
  71. Vita JA, Holbrook M, Palmisano J, Shenouda SM, Chung WB, Hamburg NM, et al. Flow-induced arterial remodeling relates to endothelial function in the human forearm. Circulation. 2008;117:3126–3133
  72. Zarins CK, Zatina MA, Giddens DP, Ku DN, Glagov S. Shear stress regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg. 1987;5:413–420
  73. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375
  74. Back MR, Maynard M, Winkler A, Bandyk DF. Expected flow parameters within hemodialysis access and selection for remedial intervention of nonmaturing conduits. Vasc Endovascular Surg. 2008;42:150–158
  75. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty (A study in the normal rabbit and the hypercholesterolemic Yucatan micropig). Circulation. 1994;89:2816–2821
  76. Skelly CL, Meyerson SL, Curi MA, Loth F, Schwartz LB. The hemodynamics of vein grafts: measurement and meaning. Ann Vasc Surg. 2001;15:110–122
  77. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension. 1991;17:187–193
  78. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science. 1985;227:1477–1479
  79. Garanich JS, Pahakis M, Tarbell JM. Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol. 2005;288:H2244–H2252
  80. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651–4655
  81. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol. 1993;264(1 Pt 2):H150–H156
  82. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376
  83. Stanley JC, Ernst CB, Fry WJ. Fate of 100 aortorenal vein grafts: characteristics of late graft expansion, aneurysmal dilatation, and stenosis. Surgery. 1973;74:931–944
  84. Upchurch GR, Gerhard-Herman MD, Sebastian MW, Belkin M, Conte MS, Donaldson MC, et al. Improved graft patency and altered remodeling in infrainguinal vein graft reconstruction for aneurysmal vs occlusive disease. J Vasc Surg. 1999;29:1022–1030
  85. Dean RH, Wilson JP, Burko H, Foster JH. Saphenous vein aortorenal bypass grafts: serial arteriographic study. Ann Surg. 1974;180:469–478
  86. Szilagyi DE, Smith RF, Elliott JP. Venous autografts in femoropopliteal arterioplasty (Observations in the treatment of occlusive disease). Arch Surg. 1964;89:113–125
  87. Fillinger MF, Cronenwett JL, Besso S, Walsh DB, Zwolak RM. Vein adaptation to the hemodynamic environment of infrainguinal grafts. J Vasc Surg. 1994;19:970–978discussion 978-9
  88. Idu MM, Buth J, Hop WC, Cuypers P, van de Pavoordt ED, Tordoir JM. Factors influencing the development of vein-graft stenosis and their significance for clinical management. Eur J Vasc Endovasc Surg. 1999;17:15–21
  89. Schanzer A, Hevelone N, Owens CD, Belkin M, Bandyk DF, Clowes AW, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007;46:1180–1190discussion 1190
  90. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization (Beyond nitric oxide and cyclic GMP). Circulation. 1995;92:3337–3349
  91. Ozaki CK. Cytokines and the early vein graft: strategies to enhance durability. J Vasc Surg. 2007;45(Suppl A):A92–A98
  92. Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F, Logerfo F, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007;45:2–9discussion 9
  93. Owens CD, Rybicki FJ, Wake N, Schanzer A, Mitsouras D, Gerhard-Herman MD, et al. Early remodeling of lower extremity vein grafts: inflammation influences biomechanical adaptation. J Vasc Surg. 2008;47:1235–1242
  94. Fortmann SP, Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation. 2004;110:e554–e559
  95. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374–379
  96. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000–1006
  97. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093–2098
  98. Gokce N, Keaney JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–1775
  99. Gokce N, Keaney JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567–1572
  100. Seidel CL, LaRochelle J. Venous and arterial endothelia: different dilator abilities in dog vessels. Circ Res. 1987;60:626–630
  101. Ignarro LJ, Buga GM, Chaudhuri G. EDRF generation and release from perfused bovine pulmonary artery and vein. Eur J Pharmacol. 1988;149:79–88
  102. Vanhoutte PM, Miller VM. Heterogeneity of endothelium-dependent responses in mammalian blood vessels. J Cardiovasc Pharmacol. 1985;7(Suppl 3):S12–S23
  103. Rubanyi GM, Vanhoutte PM. Heterogeneity of endothelium-dependent responses to acetylcholine in canine femoral arteries and veins (Separation of the role played by endothelial and smooth muscle cells). Blood Vessels. 1988;25:75–81
  104. De Mey JG, Vanhoutte PM. Heterogeneous behavior of the canine arterial and venous wall (Importance of the endothelium). Circ Res. 1982;51:439–447
  105. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med. 1988;319:462–467
  106. Schwartz LB, Radic ZS, O'Donohoe MK, Mikat EM, McCann RL, Hagen PO. Saphenous vein endothelium-dependent relaxation in patients with peripheral vascular disease. Ann Vasc Surg. 1992;6:425–432
  107. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265–9269
  108. Cross KS, Davies MG, el-Sanadiki MN, Murray JJ, Mikat EM, Hagen PO. Long-term human vein graft contractility and morphology: a functional and histopathological study of retrieved coronary vein grafts. Br J Surg. 1994;81:699–705
  109. Park TC, Harker CT, Edwards JM, Moneta GL, Taylor LM, Porter JM. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. J Vasc Surg. 1993;18:61–68discussion 68-9
  110. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation. 1991;83:402–411
  111. Davies MG, Berkowitz DE, Hagen PO. Constitutive nitric oxide synthase is expressed and nitric oxide-mediated relaxation is preserved in retrieved human aortocoronary vein grafts. J Surg Res. 1995;58:732–738
  112. Chien S. Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell. Am J Physiol Heart Circ Physiol. 2007;292:H1209–H1224
  113. Dashwood MR, Savage K, Dooley A, Shi-Wen X, Abraham DJ, Souza DS. Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. Ann Thorac Surg. 2005;80:939–944
  114. Sasaki Y, Suehiro S, Becker AE, Kinoshita H, Ueda M. Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart. 2000;83:69–75
  115. Palumbo R, Gaetano C, Melillo G, Toschi E, Remuzzi A, Capogrossi MC. Shear stress downregulation of platelet-derived growth factor receptor-beta and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation. 2000;102:225–230
  116. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science. 1986;231:405–407
  117. Rizvi MA, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol. 1997;29:1779–1789
  118. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res. 1995;76:305–309
  119. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265
  120. Owens CD, Whitmore A, Mitsourus D, Kim JM, Rybicki F, Conte MS. Radial wall stress is the primary biomechanical force determining wall thickness in human lower extremity vein grafts: assessment of wall characteristics and remodeling patterns using ultra-high resolution magnetic resonance imaging (MRI). In: 2008;Society for Vascular Surgery Vascular Annual Meeting, San Diego, Calif
  121. Wolinsky H, Glagov S. A lamellar unit of aortic medial structure and function in mammals. Circ Res. 1967;20:99–111
  122. Jacot JG, Abdullah I, Belkin M, Gerhard-Herman M, Gaccione P, Polak JF, et al. Early adaptation of human lower extremity vein grafts: wall stiffness changes accompany geometric remodeling. J Vasc Surg. 2004;39:547–555
  123. Hutter MM, Lancaster RT, Henderson WG, Khuri SF, Mosca C, Johnson RG, et al. Comparison of risk-adjusted 30-day postoperative mortality and morbidity in Department of Veterans Affairs hospitals and selected university medical centers: vascular surgical operations in men. J Am Coll Surg. 2007;204:1115–1126
  124. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934
  125. Nguyen LL, Hevelone N, Rogers SO, Bandyk DF, Clowes AW, Moneta GL, et al. Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. Circulation. 2009;119:123–130
  126. Nguyen LL, Brahmanandam S, Bandyk DF, Belkin M, Clowes AW, Moneta GL, et al. Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg. 2007;46:1191–1197
  127. Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL PREVENT III Investigators. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg. 2006;44:977–983discussion 983-4
  128. Nguyen LL, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, Belkin M, et al. Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events. J Vasc Surg. 2006;44:971–975discussion 975-6
  129. Berceli SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg. 2007;46:1173–1179
  130. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47:774–781
  131. Schanzer A, Mega J, Meadows J, Samson RH, Bandyk DF, Conte MS. Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. J Vasc Surg. 2008;48:1464–1471
  132. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005;42:456–464discussion 464-5
  133. Bradbury AW. Long-term (5-year) results of BASIL trial show “open surgery first” to be superior to “endovascular treatment first” for critical limb ischemia. http://www.veithsymposium.org/pdf/aim/1579.pdf2008;cited 2009 June 27
  134. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511–2517
  135. Grubbs AL, Anstadt MP, Ergul A. Saphenous vein endothelin system expression and activity in African American patients. Arterioscler Thromb Vasc Biol. 2002;22:1122–1127
  136. Albert MA, Ridker PM. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. Rev Cardiovasc Med. 2004;5(Suppl 3):S22–S27
  137. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464–469
  138. Geary RL, Nikkari ST, Wagner WD, Williams JK, Adams MR, Dean RH. Wound healing: a paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg. 1998;27:96–106discussion 106-8
  139. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD, Donaldson MC. Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. Ann Surg. 2001;233:445–452

 Competition of interest: none.

 The study was funded by the National Heart, Lung, and Blood Institute R01, HL75771, K23 HL 92163, and the American Vascular Association.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(09)01574-2

doi:10.1016/j.jvs.2009.07.102

Journal of Vascular Surgery
Volume 51, Issue 3 , Pages 736-746, March 2010

Article Tools

* Image Usage & Resolution